Inscrivez-vous gratuitement pour obtenir des cotations en temps réel, des graphiques interactifs, un flux d'options en direct et plus encore.

Neurogene Inc (NGNE)

39,63

-3,21

(-7,49%)

Fermé 12 Juillet 10:00PM

39,54

-0,09

(-0,23%)

Après les heures de négociation: 1:59AM

Outils de qualité professionnelle, pour des investisseurs individuels.

Premium

Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by...

Neurogene Inc. Announces Pricing of $125 Million Public Offering

Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by...

Neurogene Inc. Announces Proposed Public Offering

Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by...

Neurogene Reports Positive Long-term Clinical Data from Phase 1/2 Trial of NGN-401 Gene Therapy for Rett Syndrome

47 total developmental milestones gained across 10 participants, with durable treatment effect and no plateau or milestone loss through 30 months...

Neurogene Announces Successful Completion of Dosing in Embolden™ Registrational Trial of NGN-401 for Rett Syndrome

Exceeded target by dosing a total of 25 participants with NGN-401 in registrational trial due to strong demand from Rett syndrome community...

Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by...

Neurogene Reports First Quarter 2026 Financial Results and Highlights Recent Updates

Dosed ~90% of participants in Embolden™ registrational trial of NGN-401 for Rett syndrome; on track to complete dosing in the second quarter of...

Neurogene Highlights Data at ASGCT Meeting Supporting Therapeutic Rationale for ICV Delivery Method in CNS-targeted Gene Therapy

ICV is a commonly used neurosurgical procedure performed across multiple therapeutic settings, including gene therapy Presentation adds to body...

Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by...

Neurogene Announces Upcoming Presentation on the Therapeutic Rationale for ICV Delivery in CNS-Targeted Gene Therapy

Presentation at ASGCT Meeting will feature ICV as a routine neurosurgical procedure that provides broad biodistribution of gene therapy to the...

Neurogene Appoints Christy Shafer as Chief Commercial Officer and Christine Mikail, J.D., to Board of Directors

Ms. Shafer, a proven commercial leader in rare neurological diseases, will lead Neurogene’s commercial strategy and launch readiness for NGN-401...

Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by...

Neurogene Reports Full Year 2025 Financial Results and Highlights Recent Updates

100% of participants enrolled in Embolden™ registrational trial and >50% of participants dosed; on track to complete dosing in second quarter...

Neurogene to Participate in Stifel 2026 Virtual CNS Forum

Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by...

Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by...

Forums

Afficher les forums

Aucune Discussion Trouvée

Ajouter une Discussion

Australia and New Zealan...

Beutel Goodman Internati...

CanaFarma Hemp Products

Rapid Nutrition (EM)

Amundi MSCI Japan SRI Cl...

Grupo Simec SAB de CV

Delayed Upgrade Clock

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

ADVFN

Vous avez déjà un compte? Connexion

Vous n'avez pas de compte ? Inscription

En m'inscrivant, je confirme avoir lu, compris et accepté les Conditions générales d'ADVFN et j'affirme etre un investisseur privé.